Lexicon Pharmaceuticals LXRX Stock News

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) stock is making a run for the top in the market this morning, and for good reason. The company released positive Phase 3 data surrounding a diabetees treatment. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

LXRX Stock Rockets On Positive Data

In the press release, Lexicon Pharmaceuticals provided data from four Phase 3 clinical studies. The studies assessed sotagliflozin in patients with Type 2 diabetes. The company said that the final results of the studies will be preserved for upcoming medical congresses and publications.

While the exact data has not been shared, what we do know is that all four clinical studies met their primary endpoint objectives. In particular, LXRX said that the drug resulted in lower A1C in patients with type 2 diabetes.

Importantly, the company said that the safety profile of sotagliflozin came with a safety profile that is generally consistent with approved SGLT2 inhibitors. The most serious event seen was diarrhea. However, this is a generally common side effect for these types of treatment and was not meaningful enough to lead to treatment discontinuation.

Moreover, genital mycotic infections were seen, but proved to be dose-related. Moreover, the absolute increase in these types of infections over placebo ranged from 0% to 3.7% depending on dose.

Importantly, sotagliflozin showed less hypoglycemia that gilmepiride. In the other three studies, the incidences of hypoglycemia in patients treated with sotaglifozin were similar to the placebo results.

Finally, LXRX is seeking a partner surrounding the commercialization of the treatment in the type 2 diabetes indication. Nonetheless, once partnerships are minted, the company will seek regulatory approval.

In a statement, Pablo Lapuerta, M.D., EVP and CMO at LXRX, had the following to offer:

We are pleased with the evidence of robust A1C reduction and long-term safety in patients with type 2 diabetes demonstrated in these studies. We look forward to presenting and publishing detailed results from these studies in the future.

This News Is Huge

The fact of the matter here is that the results of four Lexicon Pharmaceuticals pivotal clinical trials were all the same. Primary endpoints were all met and a favorable safety profile was seen. That’s great news.

This is especially the case when we consider the multi-billion dollar potential of a positive drug in the diabetes market. While we will be awaiting more news on potential partnerships, this news could lead to significant revenue in the long run, making LXRX a stock that’s well worth watching.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.